Actavis Inc (ACT) 297.62 $ACT
Allergan's Pyott walks away from Actavis deal with a cool $534M
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 12:23PM CDT
ACT: 297.62 (-7.14)
Actavis sells Australian generics business
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:08AM CDT
ACT: 297.62 (-7.14)
Actavis selling Australian generic drug unit to Amneal
AP - Tue Mar 31, 6:37AM CDT
NEW YORK (AP) — Actavis PLC is selling its generic drug business in Australia to privately-held Amneal Pharmaceuticals for an undisclosed amount.
AGN: 240.22 (+2.88), ACT: 297.62 (-7.14)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone
ENDP: 89.70 (-1.83), ACT: 297.62 (-7.14), AUXL: 36.47 (-0.06), LLY: 72.65 (-1.22), ABBV: 58.54 (+0.30), CBRX: 6.21 (+0.09), ATRS: 2.71 (+0.09)
Amneal Signs Deal to Acquire the Generic Business of Actavis Australia
Business Wire - Mon Mar 30, 7:34PM CDT
Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, a subsidiary of Actavis plc (NYSE: ACT), today announced they have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis' in-country generic pharmaceuticals business for an agreed price, subject to completion of confirmatory due diligence and definitive agreements.
ACT: 297.62 (-7.14)
Mallinckrodt Reports Acthar Gel Data on Nephrotic Syndrome - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 2:41PM CDT
Mallinckrodt plc (MNK) reported two separate presentations by independent physicians on patients treated with H.P. Acthar Gel.
MNK: 126.65 (-3.48), ACT: 297.62 (-7.14), AKRX: 47.51 (-0.57), SLXP: 172.81 (+0.16)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Mon Mar 30, 9:19AM CDT
OCR: 77.06 (-0.79), ELLI: 55.31 (+0.28), JCOM: 65.68 (-2.72), CAH: 90.27 (-0.53), AET: 106.53 (-2.04), BABY: 39.47 (-0.21), DFT: 32.68 (-0.60), NLNK: 54.71 (-1.69), HSIC: 139.62 (-1.22), MNK: 126.65 (-3.48), CAVM: 70.82 (-1.93), HAS: 63.24 (+0.67), BCR: 167.35 (-2.02), MCHP: 48.90 (-0.99), MYL: 59.35 (-0.65), NXPI: 100.36 (-2.07), EV: 41.64 (-0.19), NVDA: 20.92 (-0.55), LVLT: 53.84 (-0.63), CBRL: 152.14 (-0.65), MTSI: 37.26 (+0.26), AZO: 682.16 (-7.22), EQIX: 232.85 (-1.37), IRWD: 16.00 (-0.53), AVB: 174.25 (-1.90), KNX: 32.25 (-0.10), HAE: 44.92 (-0.05), FSL: 40.76 (-0.72), FHN: 14.29 (-0.08), BDX: 143.59 (-2.05), ACT: 297.62 (-7.14), F: 16.14 (-0.02), AON: 96.12 (-1.98), NUVA: 45.99 (-0.41), CDW: 37.24 (-0.51), ANTM: 154.41 (-2.44), APH: 58.93 (+0.16), INFA: 43.85 (-0.54), EXAM: 41.62 (+0.01), LII: 111.69 (+0.32), BJRI: 50.45 (-0.79), BDN: 15.98 (-0.18), DPZ: 100.55 (-2.00), FL: 63.00 (-0.61), DLX: 69.28 (+0.50), ABT: 46.33 (-0.75), BMR: 22.66 (-0.10), HCN: 77.36 (-1.35), DIOD: 28.56 (-0.69), LEG: 46.09 (+0.10), DIS: 104.89 (-1.23), GLW: 22.68 (-0.56), MAR: 80.32 (-1.18), ASML: 101.03 (-2.09), IMAX: 33.71 (-0.29), CNC: 70.69 (-0.54), CTAS: 81.63 (-1.11), FLO: 22.74 (-0.04), CRM: 66.81 (-0.04)
Teva Phamaceutical Industries Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Mon Mar 30, 7:50AM CDT
KMI: 42.06 (-0.01), ACT: 297.62 (-7.14), JAH: 52.90 (-0.55), WBK: 29.91 (-0.35), CNQ: 30.71 (-0.12), DISH: 70.06 (-0.72), SU: 29.25 (+0.05), HCA: 75.23 (-0.94), GS: 187.97 (-3.05), JPM: 60.58 (-0.38), BAX: 68.50 (-0.26), RY: 60.36 (+1.01), TEVA: 62.30 (-0.22), SNY: 49.44 (-0.80), Y: 487.00 (-3.00), ECL: 114.38 (-0.41)
Which 4 Big Drugmakers Have Rising Estimates?
at Investor's Business Daily - Fri Mar 27, 12:16PM CDT
Drugmaker shares have been plunging this week, but the recent sell-off shouldn't necessarily be taken as an indicator that these stocks are doing poorly. Today's Screen of the Day features Leaders with Rising Estimates -- stocks with rising earnings...
LCI: 67.71 (-0.15), BIIB: 422.24 (-9.38), ACT: 297.62 (-7.14), AKRX: 47.51 (-0.57)
Has Orexigen Delivered A Death Knell To Vivus?
Spencer Osborne - at Seeking Alpha - Fri Mar 27, 9:37AM CDT
OREX: 7.83 (+0.08), ACT: 297.62 (-7.14), VVUS: 2.46 (-0.06)
Leon Cooperman's Firm Is Under Investigation and This Is Where He Is Investing His Money
at The Street - Fri Mar 27, 7:23AM CDT
Investigators looking into Leon Cooperman's Omega Advisors have quite a bit to wade through -- the billionaire has upwards of 90 securities in his public equity portfolio alone.
ACT: 297.62 (-7.14), RIG: 14.67 (-0.04), ATLS: 6.01 (-0.25), S: 4.74 (-0.01), HAL: 43.88 (+0.06), NAO: 9.16 (+0.06), LINE: 11.06 (-0.24), AIG: 54.79 (+0.11), SIRI: 3.82 (-0.05), NAVI: 20.33 (+0.25), APC: 82.81 (-1.04)
Top Large Cap Stocks That Investors Can Buy Now
Todd Campbell - at Seeking Alpha - Thu Mar 26, 2:20AM CDT
ASH: 127.31 (-1.40), OCR: 77.06 (-0.79), ACT: 297.62 (-7.14), BDX: 143.59 (-2.05), F: 16.14 (-0.02), CAH: 90.27 (-0.53), PSA: 197.14 (-2.05), SLG: 128.38 (-1.17), AON: 96.12 (-1.98), AET: 106.53 (-2.04), VTR: 73.02 (-0.63), CDW: 37.24 (-0.51), ANTM: 154.41 (-2.44), APH: 58.93 (+0.16), Q: 66.97 (-1.03), FL: 63.00 (-0.61), HSIC: 139.62 (-1.22), APD: 151.28 (-2.52), HAS: 63.24 (+0.67), ABT: 46.33 (-0.75), BCR: 167.35 (-2.02), HCN: 77.36 (-1.35), ORLY: 216.24 (-3.14), MCHP: 48.90 (-0.99), MYL: 59.35 (-0.65), DIS: 104.89 (-1.23), NXPI: 100.36 (-2.07), GLW: 22.68 (-0.56), MAR: 80.32 (-1.18), BA: 150.08 (-2.62), WAT: 124.32 (-0.62), ASML: 101.03 (-2.09), NVDA: 20.92 (-0.55), LVLT: 53.84 (-0.63), CTAS: 81.63 (-1.11), PLL: 100.39 (-1.24), AZO: 682.16 (-7.22), EQIX: 232.85 (-1.37), AVB: 174.25 (-1.90), SUNE: 24.00 (-0.19), TDG: 218.72 (-1.11), BEAV: 63.62 (-0.37), SHW: 284.50 (+0.26), FSL: 40.76 (-0.72), CRM: 66.81 (-0.04)
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 25, 10:10AM CDT
Investors should add healthcare ETFs to their portfolio for some outperformance given bullish trends in the sector.
RYH: 155.22 (-2.05), BIIB: 422.24 (-9.38), IHF: 133.06 (-1.07), ACT: 297.62 (-7.14), VRX: 198.62 (-2.76), MRK: 57.48 (-0.86), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), PTH: 60.60 (-1.08), XHS: 124.42 (-0.51), SLXP: 172.81 (+0.16), ABBV: 58.54 (+0.30)
Technical Analysis on Pharma Equities -- Zoetis, Horizon Pharma, Valeant Pharma Intl., Actavis, and Medicines
PR Newswire - Wed Mar 25, 8:57AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ZTS: 46.29 (-0.63), ACT: 297.62 (-7.14), VRX: 198.62 (-2.76), MDCO: 28.02 (-0.34), HZNP: 25.97 (+0.19), VRX.TO: 250.21 (-6.46)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ACT: 297.62 (-7.14), AIRM: 46.59 (-0.16), CENT: 9.87 (-0.21), AEZS: 0.53 (unch), AAPL: 124.43 (-1.94)
Trevena's Q4 2014 Results Conference Call - What We Learned
Scrying Biotech - at Seeking Alpha - Mon Mar 23, 12:14PM CDT
TRVN: 6.52 (-0.12), ACT: 297.62 (-7.14)
5 Rocket Stocks That Are Ready for Blastoff
at The Street - Mon Mar 23, 7:21AM CDT
These stocks have both short-term gain catalysts and longer-term growth potential.
ACT: 297.62 (-7.14), RAX: 51.59 (-0.79), ADI: 63.00 (-1.81), FL: 63.00 (-0.61), HOT: 83.50 (-0.83)
Vivus: Qsymia Sales Slip, Company Needs To Shift Into Gear
Spencer Osborne - at Seeking Alpha - Mon Mar 23, 5:51AM CDT
OREX: 7.83 (+0.08), ACT: 297.62 (-7.14), VVUS: 2.46 (-0.06), ARNA: 4.37 (-0.11)
Drug Stocks Are Hot: Meet The 5 Best On The IBD 50
at Investor's Business Daily - Sat Mar 21, 7:02AM CDT
Today's IBD 50 roundup features five top drugmakers that have been making headlines. Even though they've all now extended past buying range, they may yet form new bases, and investors won't want to be late to blink-and-you'll-miss-it key price...
ENDP: 89.70 (-1.83), BIIB: 422.24 (-9.38), VRX: 198.62 (-2.76), ACT: 297.62 (-7.14), AKRX: 47.51 (-0.57), SLXP: 172.81 (+0.16)
Allergan's Pyott walks away from Actavis deal with a cool $534M
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 12:23PM CDT
ACT: 297.62 (-7.14)
Actavis sells Australian generics business
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:08AM CDT
ACT: 297.62 (-7.14)
Actavis selling Australian generic drug unit to Amneal
AP - Tue Mar 31, 6:37AM CDT
NEW YORK (AP) — Actavis PLC is selling its generic drug business in Australia to privately-held Amneal Pharmaceuticals for an undisclosed amount.
AGN: 240.22 (+2.88), ACT: 297.62 (-7.14)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone ENDP: 89.70 (-1.83), ACT: 297.62 (-7.14), AUXL: 36.47 (-0.06), LLY: 72.65 (-1.22), ABBV: 58.54 (+0.30), CBRX: 6.21 (+0.09), ATRS: 2.71 (+0.09)
Amneal Signs Deal to Acquire the Generic Business of Actavis Australia
Business Wire - Mon Mar 30, 7:34PM CDT
Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, a subsidiary of Actavis plc (NYSE: ACT), today announced they have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis' in-country generic pharmaceuticals business for an agreed price, subject to completion of confirmatory due diligence and definitive agreements.
ACT: 297.62 (-7.14)
Mallinckrodt Reports Acthar Gel Data on Nephrotic Syndrome - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 2:41PM CDT
Mallinckrodt plc (MNK) reported two separate presentations by independent physicians on patients treated with H.P. Acthar Gel.
MNK: 126.65 (-3.48), ACT: 297.62 (-7.14), AKRX: 47.51 (-0.57), SLXP: 172.81 (+0.16)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Mon Mar 30, 9:19AM CDT
OCR: 77.06 (-0.79), ELLI: 55.31 (+0.28), JCOM: 65.68 (-2.72), CAH: 90.27 (-0.53), AET: 106.53 (-2.04), BABY: 39.47 (-0.21), DFT: 32.68 (-0.60), NLNK: 54.71 (-1.69), HSIC: 139.62 (-1.22), MNK: 126.65 (-3.48), CAVM: 70.82 (-1.93), HAS: 63.24 (+0.67), BCR: 167.35 (-2.02), MCHP: 48.90 (-0.99), MYL: 59.35 (-0.65), NXPI: 100.36 (-2.07), EV: 41.64 (-0.19), NVDA: 20.92 (-0.55), LVLT: 53.84 (-0.63), CBRL: 152.14 (-0.65), MTSI: 37.26 (+0.26), AZO: 682.16 (-7.22), EQIX: 232.85 (-1.37), IRWD: 16.00 (-0.53), AVB: 174.25 (-1.90), KNX: 32.25 (-0.10), HAE: 44.92 (-0.05), FSL: 40.76 (-0.72), FHN: 14.29 (-0.08), BDX: 143.59 (-2.05), ACT: 297.62 (-7.14), F: 16.14 (-0.02), AON: 96.12 (-1.98), NUVA: 45.99 (-0.41), CDW: 37.24 (-0.51), ANTM: 154.41 (-2.44), APH: 58.93 (+0.16), INFA: 43.85 (-0.54), EXAM: 41.62 (+0.01), LII: 111.69 (+0.32), BJRI: 50.45 (-0.79), BDN: 15.98 (-0.18), DPZ: 100.55 (-2.00), FL: 63.00 (-0.61), DLX: 69.28 (+0.50), ABT: 46.33 (-0.75), BMR: 22.66 (-0.10), HCN: 77.36 (-1.35), DIOD: 28.56 (-0.69), LEG: 46.09 (+0.10), DIS: 104.89 (-1.23), GLW: 22.68 (-0.56), MAR: 80.32 (-1.18), ASML: 101.03 (-2.09), IMAX: 33.71 (-0.29), CNC: 70.69 (-0.54), CTAS: 81.63 (-1.11), FLO: 22.74 (-0.04), CRM: 66.81 (-0.04)
Teva Phamaceutical Industries Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Mon Mar 30, 7:50AM CDT
KMI: 42.06 (-0.01), ACT: 297.62 (-7.14), JAH: 52.90 (-0.55), WBK: 29.91 (-0.35), CNQ: 30.71 (-0.12), DISH: 70.06 (-0.72), SU: 29.25 (+0.05), HCA: 75.23 (-0.94), GS: 187.97 (-3.05), JPM: 60.58 (-0.38), BAX: 68.50 (-0.26), RY: 60.36 (+1.01), TEVA: 62.30 (-0.22), SNY: 49.44 (-0.80), Y: 487.00 (-3.00), ECL: 114.38 (-0.41)
Which 4 Big Drugmakers Have Rising Estimates?
at Investor's Business Daily - Fri Mar 27, 12:16PM CDT
Drugmaker shares have been plunging this week, but the recent sell-off shouldn't necessarily be taken as an indicator that these stocks are doing poorly. Today's Screen of the Day features Leaders with Rising Estimates -- stocks with rising earnings...
LCI: 67.71 (-0.15), BIIB: 422.24 (-9.38), ACT: 297.62 (-7.14), AKRX: 47.51 (-0.57)
Has Orexigen Delivered A Death Knell To Vivus?
Spencer Osborne - at Seeking Alpha - Fri Mar 27, 9:37AM CDT
OREX: 7.83 (+0.08), ACT: 297.62 (-7.14), VVUS: 2.46 (-0.06)
Leon Cooperman's Firm Is Under Investigation and This Is Where He Is Investing His Money
at The Street - Fri Mar 27, 7:23AM CDT
Investigators looking into Leon Cooperman's Omega Advisors have quite a bit to wade through -- the billionaire has upwards of 90 securities in his public equity portfolio alone.
ACT: 297.62 (-7.14), RIG: 14.67 (-0.04), ATLS: 6.01 (-0.25), S: 4.74 (-0.01), HAL: 43.88 (+0.06), NAO: 9.16 (+0.06), LINE: 11.06 (-0.24), AIG: 54.79 (+0.11), SIRI: 3.82 (-0.05), NAVI: 20.33 (+0.25), APC: 82.81 (-1.04)
Top Large Cap Stocks That Investors Can Buy Now
Todd Campbell - at Seeking Alpha - Thu Mar 26, 2:20AM CDT
ASH: 127.31 (-1.40), OCR: 77.06 (-0.79), ACT: 297.62 (-7.14), BDX: 143.59 (-2.05), F: 16.14 (-0.02), CAH: 90.27 (-0.53), PSA: 197.14 (-2.05), SLG: 128.38 (-1.17), AON: 96.12 (-1.98), AET: 106.53 (-2.04), VTR: 73.02 (-0.63), CDW: 37.24 (-0.51), ANTM: 154.41 (-2.44), APH: 58.93 (+0.16), Q: 66.97 (-1.03), FL: 63.00 (-0.61), HSIC: 139.62 (-1.22), APD: 151.28 (-2.52), HAS: 63.24 (+0.67), ABT: 46.33 (-0.75), BCR: 167.35 (-2.02), HCN: 77.36 (-1.35), ORLY: 216.24 (-3.14), MCHP: 48.90 (-0.99), MYL: 59.35 (-0.65), DIS: 104.89 (-1.23), NXPI: 100.36 (-2.07), GLW: 22.68 (-0.56), MAR: 80.32 (-1.18), BA: 150.08 (-2.62), WAT: 124.32 (-0.62), ASML: 101.03 (-2.09), NVDA: 20.92 (-0.55), LVLT: 53.84 (-0.63), CTAS: 81.63 (-1.11), PLL: 100.39 (-1.24), AZO: 682.16 (-7.22), EQIX: 232.85 (-1.37), AVB: 174.25 (-1.90), SUNE: 24.00 (-0.19), TDG: 218.72 (-1.11), BEAV: 63.62 (-0.37), SHW: 284.50 (+0.26), FSL: 40.76 (-0.72), CRM: 66.81 (-0.04)
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 25, 10:10AM CDT
Investors should add healthcare ETFs to their portfolio for some outperformance given bullish trends in the sector.
RYH: 155.22 (-2.05), BIIB: 422.24 (-9.38), IHF: 133.06 (-1.07), ACT: 297.62 (-7.14), VRX: 198.62 (-2.76), MRK: 57.48 (-0.86), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), PTH: 60.60 (-1.08), XHS: 124.42 (-0.51), SLXP: 172.81 (+0.16), ABBV: 58.54 (+0.30)
Technical Analysis on Pharma Equities -- Zoetis, Horizon Pharma, Valeant Pharma Intl., Actavis, and Medicines
PR Newswire - Wed Mar 25, 8:57AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ZTS: 46.29 (-0.63), ACT: 297.62 (-7.14), VRX: 198.62 (-2.76), MDCO: 28.02 (-0.34), HZNP: 25.97 (+0.19), VRX.TO: 250.21 (-6.46)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
ACT: 297.62 (-7.14), AIRM: 46.59 (-0.16), CENT: 9.87 (-0.21), AEZS: 0.53 (unch), AAPL: 124.43 (-1.94)
Trevena's Q4 2014 Results Conference Call - What We Learned
Scrying Biotech - at Seeking Alpha - Mon Mar 23, 12:14PM CDT
TRVN: 6.52 (-0.12), ACT: 297.62 (-7.14)
5 Rocket Stocks That Are Ready for Blastoff
at The Street - Mon Mar 23, 7:21AM CDT
These stocks have both short-term gain catalysts and longer-term growth potential.
ACT: 297.62 (-7.14), RAX: 51.59 (-0.79), ADI: 63.00 (-1.81), FL: 63.00 (-0.61), HOT: 83.50 (-0.83)
Vivus: Qsymia Sales Slip, Company Needs To Shift Into Gear
Spencer Osborne - at Seeking Alpha - Mon Mar 23, 5:51AM CDT
OREX: 7.83 (+0.08), ACT: 297.62 (-7.14), VVUS: 2.46 (-0.06), ARNA: 4.37 (-0.11)
Drug Stocks Are Hot: Meet The 5 Best On The IBD 50
at Investor's Business Daily - Sat Mar 21, 7:02AM CDT
Today's IBD 50 roundup features five top drugmakers that have been making headlines. Even though they've all now extended past buying range, they may yet form new bases, and investors won't want to be late to blink-and-you'll-miss-it key price...
ENDP: 89.70 (-1.83), BIIB: 422.24 (-9.38), VRX: 198.62 (-2.76), ACT: 297.62 (-7.14), AKRX: 47.51 (-0.57), SLXP: 172.81 (+0.16)
